Arcus Biosciences (NYSE:RCUS) Stock Gets Downgrade from Wall Street Zen

Arcus Biosciences (NYSE:RCUS) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Several other equities analysts also recently issued reports on the stock. The Goldman Sachs Group reaffirmed a “buy” rating and set a $42.00 price target on shares of Arcus Biosciences in a research note on Friday, August 7th. Wells Fargo & Company lifted their price target on shares of Arcus Biosciences from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Thursday, August 6th. HC Wainwright boosted their price objective on shares of Arcus Biosciences from $32.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. JPMorgan Chase & Co. initiated coverage on shares of Arcus Biosciences in a research note on Wednesday, October 14th. They issued an “overweight” rating and a $41.00 price objective on the stock. Finally, TD Cowen assumed coverage on Arcus Biosciences in a report on Wednesday, September 16th. They issued a “buy” rating for the company. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Arcus Biosciences currently has an average rating of “Moderate Buy” and an average price target of $39.64.

Arcus Biosciences Stock Performance

NYSE:RCUS opened at $18.54 on Friday. The stock has a market cap of $2.36 billion, a P/E ratio of -4.75 and a beta of 0.94. The company has a current ratio of 3.82, a quick ratio of 3.82 and a debt-to-equity ratio of 0.22. The stock’s 50-day moving average is $26.12 and its 200-day moving average is $26.17. Arcus Biosciences has a 1-year low of $16.87 and a 1-year high of $31.74.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.17. The company had revenue of $41.00 million during the quarter, compared to the consensus estimate of $21.98 million. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%. The company’s quarterly revenue was down 74.4% compared to the same quarter last year. Equities research analysts anticipate that Arcus Biosciences will post -3.55 earnings per share for the current year.

Insider Buying and Selling at Arcus Biosciences

In other news, CAO Alexander Azoy sold 2,827 shares of Arcus Biosciences stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $30.00, for a total value of $84,810.00. Following the completion of the transaction, the chief accounting officer directly owned 39,581 shares of the company’s stock, valued at approximately $1,187,430. This trade represents a 6.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in RCUS. Bank of New York Mellon Corp bought a new stake in Arcus Biosciences in the second quarter worth approximately $16,741,000. Legal & General Group Plc acquired a new position in Arcus Biosciences in the second quarter valued at approximately $5,906,000. BlackRock Inc. acquired a new position in Arcus Biosciences in the second quarter valued at approximately $506,113,000. Corient Private Wealth LP bought a new position in shares of Arcus Biosciences during the 2nd quarter worth approximately $1,823,000. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Arcus Biosciences during the 1st quarter worth approximately $1,862,000. 92.89% of the stock is owned by institutional investors and hedge funds.

Arcus Biosciences News Roundup

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Analyst support: Truist Financial and Wedbush both forecast strong price appreciation for RCUS, suggesting analysts see upside following the recent selloff. Truist Financial Forecasts Strong Price Appreciation for Arcus Biosciences Wedbush Forecasts Strong Price Appreciation for Arcus Biosciences
• Positive Sentiment: Promising casdatifan data: Arcus presented new ARC-20 data evaluating casdatifan across multiple lines of therapy in kidney cancer. The results may support the drug’s development and commercial potential, though investors are likely seeking additional details on efficacy and durability. Arcus Presents New Casdatifan Data
• Neutral Sentiment: Improved liquidity: Arcus estimates it held approximately $694 million in cash, cash equivalents and marketable securities as of September 30, 2026. Proceeds from the offering should further extend its funding runway for clinical development, but the benefit comes with shareholder dilution. Arcus Estimates Cash Position
• Negative Sentiment: Equity dilution: Arcus priced an underwritten public offering of 14.29 million shares at $17.50 per share, expected to raise $250 million before expenses. The discounted issuance increases the share count and was the primary catalyst for the stock’s decline. Arcus Prices $250 Million Offering
• Negative Sentiment: Investor litigation risk: Kuehn Law said it is investigating potential fiduciary-duty violations and alleged self-dealing by company officers and directors. The announcement does not establish wrongdoing, but it adds reputational and legal uncertainty. Kuehn Law Investigation

About Arcus Biosciences

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets.